CompletedPhase 2/3

Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

334 participantsStarted 2008-08-21

Plain-language summary

Determination of the effect of balugrastim on the duration and severity of severe neutropenia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Breast cancer participants scheduled to receive the AT regimen (doxorubicin/ docetaxel). Exclusion Criteria: * Participants may have received no more than 1 prior chemotherapy regimen (including adjuvant therapy if given within the last 12 months).

What they're measuring

Duration of Severe Neutropenia in Cycle 1

Timeframe: Cycle 1 (cycle length = 21 days)

Trial details

NCT IDNCT00837265

SponsorTeva Branded Pharmaceutical Products R&D, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2009-06-26

Results submitted2023-01-09

View on ClinicalTrials.gov More Chemotherapy-induced Neutropenia trials